A Randomized Open-Label Phase III Trial of MK-3475 Versus Platinum Based Chemotherapy in 1L Subjects With PD-L1 Strong Metastatic Non-Small Cell Lung Cancer

Trial Profile

A Randomized Open-Label Phase III Trial of MK-3475 Versus Platinum Based Chemotherapy in 1L Subjects With PD-L1 Strong Metastatic Non-Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Carboplatin; Cisplatin; Gemcitabine; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms KEYNOTE-024
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 29 Sep 2017 According to a Merck AG media release, data will be presented at the 18th World Conference on Lung Cancer (WCLC).
    • 20 Sep 2017 According to a Merck & Co media release, based on the data from this study, Pembrolizumab is approved in Canada for the treatment of patients with unresectable or metastatic melanoma, in adults whose tumours have high PD-L1 expression, with no EGFR or ALK genomic tumour aberrations and no prior systemic chemotherapy treatment.
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top